University of Nebraska Medical Center, Center for Continuing Education and oneconsortium
Last Modified: April 13, 2010
Conference Dates: June 19, 2010
Conference Location: Chicago, Illinois
Sponsoring Group: Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and oneconsortium
Conference Web Page URL: www.thecbce.com/lungtownhall
Topics Covered: This interactive, town hall program focuses on the latest advances in the treatment of non–small cell lung cancer (NSCLC). Recent developments include emerging roles for novel targeted and chemotherapeutic agents, maintenance therapy, and the importance of using tumor characteristics in treatment selection. This program reviews the latest developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for treatment decision making in the management of patients with NSCLC. Clinical trial updates are discussed in the context of clinical scenarios to assess the impact of current research on patient care.
Conference Objectives: Upon completion of this activity, participants will be able to
Who Should Attend: This activity is intended for medical oncologists, thoracic surgeons, advanced practitioners, physician assistants, pulmonologists, radiologists, and other healthcare professionals involved in the treatment of patients with NSCLC.
Registration Information: Registration for this educational activity is free. Please visit www.thecbce.com/lungtownhall to register.
Conference Fees: Free
Continuing Education: Yes
Miscellany: A Studio-Based Town Hall Meeting
Dec 16, 2010 - Using a tool based on six gene markers, oncologists may be better able to identify stage I non-small-cell lung cancer patients more at risk for relapse who might benefit from adjuvant therapy, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, held from Dec. 9 to 11.
Dec 16, 2010
Dec 21, 2014
Dec 21, 2014